keyword
https://read.qxmd.com/read/38604785/-expert-consensus-on-clonal-screening-and-monitoring-of-complement-inhibitor-therapy-in-paroxysmal-nocturnal-hemoglobinuria-2024
#21
JOURNAL ARTICLE
(no author information available yet)
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal disease with abnormal hematopoietic stem cells that causes intravascular hemolytic anemia, thrombosis, and peripheral blood cytopenia. It has a chronic progressive course and can be fatal in severe cases if not treated aggressively. Complement inhibitors are the first-line recommended treatment for hemolysis-related symptoms of PNH. With the rapid development of new complement inhibitors, it is critical to quickly screen and confirm the diagnosis, identify patients with complement inhibitor indications, and monitor breakthrough hemolysis and extravascular hemolysis during complement inhibitor therapy...
February 14, 2024: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://read.qxmd.com/read/38603657/real-world-challenges-of-managing-diffuse-large-b-cell-lymphoma-in-a-developing-country
#22
MULTICENTER STUDY
Raheel Iftikhar, Usman Ahmad, Ghulam Haider, Humera Mahmood, Maryam Khan, Misbah Masood, Nida Anwar, Qamar Javed, Nadia Sajid, Rija Tariq, Sana Mehmod, Javeria Haider, Nargis Aalam Abro, Shanzah Shahbaz, Abbas Khokhar, Zeeshan Ahmed Khan, Hassan Pervez, Munira Moosajee, Zeba Aziz
PURPOSE: To highlight challenges and cancer care disparities in patients of diffuse large B-cell lymphoma management in resource-constrained settings. MATERIALS AND METHODS: This multicenter retrospective study included 738 patients from 12 public and private sector hematology-oncology centers across Pakistan. Patients were divided into limited-resource and enhanced-resource settings as per national diffuse large B-cell lymphoma (DLBCL) guidelines. RESULTS: The median age at diagnosis was 47 years (range, 14-89)...
April 2024: JCO global oncology
https://read.qxmd.com/read/38600802/british-society-for-haematology-guidelines-to-improve-the-care-of-asplenic-patients-much-work-done-some-remaining-and-a-call-for-national-registries
#23
JOURNAL ARTICLE
Etienne Rivière
Asplenic patients are at high risk of serious infectious or thrombotic complications, especially when they are not adequately informed of the risk and not closely followed. Ladhani et al. on behalf of the British Society for Haematology propose updated guidelines for managing these patients. Healthcare professionals need to improve infection prevention in patients with hypofunctional or absent spleen through better identification and immunisation using established national registries. Commentary on: Ladhani et al...
April 10, 2024: British Journal of Haematology
https://read.qxmd.com/read/38600782/prevention-and-treatment-of-infection-in-patients-with-an-absent-or-hypofunctional-spleen-a-british-society-for-haematology-guideline
#24
JOURNAL ARTICLE
Shamez N Ladhani, Savio Fernandes, Mamta Garg, Ray Borrow, Simon de Lusignan, Paula H B Bolton-Maggs
Guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen were published by the British Committee for Standards in Haematology in 1996 and updated in 2002 and 2011. With advances in vaccinations and changes in patterns of infection, the guidelines required updating. Key aspects included in this guideline are the identification of patients at risk of infection, patient education and information and immunisation schedules. This guideline does not address the non-infective complications of splenectomy or functional hyposplenism (FH)...
April 10, 2024: British Journal of Haematology
https://read.qxmd.com/read/38600674/comparison-of-two-autologous-hematopoietic-stem-cell-mobilization-strategies-in-patients-with-multiple-myeloma-ce-plus-g-csf-versus-g-csf-only-a-single-center-retrospective-analysis
#25
JOURNAL ARTICLE
Veronika Dill, Philipp Blüm, Anja Lindemann, Alexander Biederstädt, Marion Högner, Katharina S Götze, Florian Bassermann, Martin Hildebrandt
BACKGROUND: Despite recent advances in the treatment of multiple myeloma, high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (ASCT) remains an essential therapeutic keystone. As for the stem cell mobilization procedure, different regimens have been established, usually consisting of a cycle of chemotherapy followed by application of granulocyte-colony stimulating factor (G-CSF), although febrile neutropenia is a common complication. Following national guidelines, our institution decided to primarily use G-CSF only mobilization during the COVID-19 pandemic to minimize the patients' risk of infection and to reduce the burden on the health system...
April 10, 2024: Transfusion
https://read.qxmd.com/read/38593461/distinguishing-ash-clinical-practice-guidelines-from-other-forms-of-ash-clinical-advice
#26
JOURNAL ARTICLE
Adam Cuker, Robert Kunkle, Rachel Sara Bercovitz, Michael T Byrne, Benjamin Djulbegovic, Sandra L Haberichter, Jennifer Holter-Chakrabarty, Richard Lottenberg, Menaka Pai, Suely Meireles Rezende, Matthew D Seftel, Roy L Silverstein, Deirdra R Terrell, Matthew C Cheung
The American Society of Hematology (ASH) develops a variety of resources that provide guidance to clinicians on the diagnosis and management of blood diseases. These resources include clinical practice guidelines (CPGs) and other forms of clinical advice. While both ASH CPGs and other forms of clinical advice provide recommendations, they differ with respect to the methods underpinning their development, the principal type of recommendations they offer, their transparency and concordance with published evidence, and the time and resources required for their development...
April 9, 2024: Blood Advances
https://read.qxmd.com/read/38590088/the-car-t-cell-race-the-rules-of-the-game
#27
JOURNAL ARTICLE
Adriana Balduzzi
The management of paediatric patients with refractory acute lymphoblastic leukaemia eligible for the CAR T cell product tisagenlecleucel involves multiple decision points between the process of patient referral to product infusion. How to address the individual patient's circumstances, optimize apheresis yields and, above all, plan the best bridging chemotherapy is clearly detailed in these comprehensive and practical recommendations by Kumar Mishra and colleagues. Commentary on: Mishra et al. Practice guideline: Preparation for CAR T-cell therapy in children and young adults with B-acute lymphoblastic leukaemia...
April 8, 2024: British Journal of Haematology
https://read.qxmd.com/read/38588525/current-and-emerging-pharmacotherapies-for-cytokine-release-syndrome-neurotoxicity-and-hemophagocytic-lymphohistiocytosis-like-syndrome-due-to-car-t-cell-therapy
#28
REVIEW
Zandra E Walton, Matthew J Frigault, Marcela V Maus
INTRODUCTION: Chimeric antigen receptor (CAR) T cells have revolutionized treatment of multiple hematologic malignancies. Engineered cellular therapies now offer similar hope to transform management of solid tumors and autoimmune disease. However, toxicities can be serious and often require hospitalization. AREAS COVERED: We review the two chief toxicities of CAR T therapy, cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), and the rarer immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome...
April 8, 2024: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/38582056/appraisal-of-the-clinical-practice-guidelines-on-thromboprophylaxis-in-orthopaedic-procedures-do-we-agree-ii
#29
REVIEW
Maria P Ntalouka, Antonis Koutalos, Fragkiskos Angelis, Metaxia Bareka, Michael Hantes, Theofilos Karachalios, Eleni Arnaoutoglou
OBJECTIVE: Optimal thromboprophylaxis in orthopaedic procedures is crucial in an attempt to lower the risk of venous thromboembolism, including deep vein thrombosis and pulmonary embolism. We aim to: 1) identify clinical practice guidelines (CPGs) and recommendations (CPRs) on thromboprophylaxis in adult patients undergoing orthopaedic procedures, and 2) assess the methodological quality and reporting clarity of these guidelines. METHODS: The study was conducted following the 2020 PRISMA guidelines for a systematic review and has been registered on the international prospective register of systematic reviews (PROSPERO) under the registration number (CRD42023406988)...
April 2, 2024: Injury
https://read.qxmd.com/read/38582045/safety-and-efficacy-of-chimeric-antigen-receptor-t-cell-therapy-for-acute-myeloid-leukemia-a-subgroup-based-meta-analysis
#30
JOURNAL ARTICLE
Mahmoud M Morsy, Ahmed Y Azzam, Osman Elamin, Adam Elswedy, Abdulqadir J Nashwan
INTRODUCTION: Acute myeloid leukemia (AML) is a significant hematological malignancy in the United States, with a high mortality rate and limited treatment options. CAR T-cell therapy, a new and promising treatment, is being investigated for its efficacy and safety in AML. This meta-analysis aims to assess the safety and efficacy of CAR T-cell therapy in AML, considering various subgroups such as study location, study design, prior transplantation status, conditioning regimen, and CAR T-cell source...
April 1, 2024: Leukemia Research
https://read.qxmd.com/read/38581269/leading-digit-bias-in-hemoglobin-thresholds-for-red-cell-transfusion
#31
JOURNAL ARTICLE
Sheharyar Raza, Malcolm Risk, Christine Cserti-Gazdewich
BACKGROUND: Leading digit bias is a heuristic whereby humans overemphasize the left-most digit when evaluating numbers (e.g., 9.99 vs. 10.00). The bias might affect the interpretation of hemoglobin results and influence red cell transfusion in hospitalized patients. STUDY DESIGN AND METHODS: Adults who received a red cell transfusion while registered at the University Health Network (Toronto, Canada) between January 1, 2016 and January 1, 2022 (n = 6 years) were included...
April 6, 2024: Transfusion
https://read.qxmd.com/read/38578212/evaluating-thromboprophylaxis-in-the-sickle-cell-disease-population-navigating-the-evidence-gap
#32
REVIEW
Jennifer Davila, Sarah H O'Brien, William B Mitchell, Deepa Manwani
Sickle cell disease (SCD) arises from beta-globin gene mutations, with global estimates indicating around 500 000 affected neonates in 2021. In the United States, it is considered rare, impacting fewer than 200 000 individuals. The key pathogenic flaw lies in mutant haemoglobin S, prone to polymerization under low oxygen conditions, causing erythrocytes to adopt a sickled shape. This leads to complications like vascular occlusion, haemolytic anaemia, inflammation and organ damage. Beyond erythrocyte abnormalities however, there is a body of literature highlighting the hypercoagulable state that is likely a contributor to many of the complications we see in SCD...
April 5, 2024: British Journal of Haematology
https://read.qxmd.com/read/38575822/tumor-lysis-syndrome-in-induction-therapy-for-acute-myeloid-leukemia-before-the-rasburicase-era
#33
JOURNAL ARTICLE
Yumiko Toda, Masahiro Ashizawa, Rui Murahashi, Hirotomo Nakashima, Takashi Ikeda, Shin-Ichiro Kawaguchi, Takashi Nagayama, Kento Umino, Daisuke Minakata, Kaoru Morita, Chihiro Yamamoto, Kaoru Hatano, Kazuya Sato, Shin-Ichiro Fujiwara, Ken Ohmine, Yoshinobu Kanda
Guidelines recommend rasburicase for high-risk patients to prevent tumor lysis syndrome (TLS). However, little information is available on the incidence and outcome of TLS in AML patients. We analyzed 145 patients with AML who underwent induction therapy before the approval of rasburicase to evaluate the incidence of TLS and the necessity of rasburicase as prophylaxis. Three patients had already developed clinical TLS (CTLS) at diagnosis of AML, and another three developed CTLS after the initiation of chemotherapy...
April 5, 2024: International Journal of Hematology
https://read.qxmd.com/read/38569461/geriatric-assessment-identified-impairments-and-frailty-in-adults-with-cancer-younger-than-65-an-opportunity-to-optimize-oncology-care
#34
JOURNAL ARTICLE
Mackenzi Pergolotti, Kelley C Wood, Mary Hidde, Tiffany D Kendig, Ellen A Ronnen, Smith Giri, Grant R Williams
INTRODUCTION: Frailty, a state of increased vulnerability to stressors due to aging or treatment-related accelerated aging, is associated with declines in physical, cognitive and/or social functioning, and quality of life for cancer survivors. For survivors aged <65 years, little is known about frailty status and associated impairments to inform intervention. We aimed to evaluate the prevalence of frailty and contributing geriatric assessment (GA)-identified impairments in adults aged <65 versus ≥65 years with cancer...
April 2, 2024: Journal of Geriatric Oncology
https://read.qxmd.com/read/38569136/industry-payments-to-american-society-of-hematology-clinical-practice-guideline-authors
#35
JOURNAL ARTICLE
Jeremy Jacobs, Garrett S Booth, Laura D Stephens, Brian D Adkins, Amarilis A Martin, George D Lundberg, Raeshun Trey Glover, Shazia S Khan, Julie K Silver, Jennifer S Woo
No abstract text is available yet for this article.
April 3, 2024: Blood Advances
https://read.qxmd.com/read/38561279/-guideline-for-the-diagnosis-and-management-of-multiple-myeloma-related-renal-impairment-2024-version
#36
JOURNAL ARTICLE
(no author information available yet)
Renal impairment is a common complication of multiple myeloma (MM). All patients with MM should be assessed for the presence and severity of renal impairment. The clinicopathological manifestations of MM-related renal impairment are diverse and complex; accordingly, except for light-chain nephropathy, which can often be diagnosed without biopsy based solely on clinical criteria, a renal biopsy is needed for an accurate diagnosis. Supportive care, such as adequate hydration, is required for all patients with MM-related renal impairment...
April 1, 2024: Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]
https://read.qxmd.com/read/38558108/clinical-guidelines-for-prevention-and-treatment-of-cat-in-japan-and-other-countries
#37
REVIEW
Yoshinobu Seki
Cancer-associated thrombosis (CAT) is an important prognostic factor for an increasing number of cancer patients. Understanding of CAT among cancer care providers has grown in recent years, and guidelines for the prevention and treatment of CAT have been published in Japan and around the world. In this article, we introduce these major guidelines and discuss differences we identified between the Japanese guidelines and those of other countries, with a focus on problems and issues. Insurance coverage of low-molecular-weight heparin and indications for primary prevention with direct oral anticoagulants in particular require urgent consideration...
April 1, 2024: International Journal of Hematology
https://read.qxmd.com/read/38556719/implementation-of-a-light-therapy-team-to-administer-photobiomodulation-therapy-a-standardized-protocol-to-prevent-and-treat-oral-mucositis-in-the-pediatric-hematopoietic-stem-cell-transplant-population
#38
JOURNAL ARTICLE
Kathleen Magee, Jenell Robins, Sharon Staton, Gabriella Llaurador, Alexandra M Stevens
BACKGROUND: Oral mucositis (OM) is a painful and common complication of hematopoietic stem cell transplant (HSCT). The Children's Oncology Group recently published guidelines recommending photobiomodulation (PBM) for preventing and treating OM in pediatric HSCT patients. However, this is a rarely used intervention in pediatric hospitals. PROCEDURE: Patients undergoing allogeneic HSCT, or autologous HSCT for a neuroblastoma diagnosis, had PBM administered from the first day of conditioning to transplant Day +20...
March 31, 2024: Pediatric Blood & Cancer
https://read.qxmd.com/read/38556718/management-of-undifferentiated-embryonal-sarcoma-of-the-liver-a-pediatric-surgical-oncology-research-collaborative-study
#39
JOURNAL ARTICLE
Zachary J Kastenberg, Scott S Short, Kimberly J Riehle, Alan Utria, Timothy B Lautz, Katherine C Ott, Andrew J Murphy, Sara Mansfield, Dave R Lal, Brian Hallis, Joseph T Murphy, Jonathan P Roach, Stephanie F Polites, Catherine Beckhorn, Elisabeth T Tracy, Elizabeth A Fialkowski, Natashia M Seemann, Andreana M Bütter, Barrie S Rich, Richard D Glick, Alex J Bondoc, Blessing S Ofori-Atta, Angela P Presson, Stephanie Y Chen, Abigail K Zamora, Eugene S Kim, Sanjeev Vasudevan, Hannah N Rinehardt, Marcus M Malek, Eveline Lapidus-Krol, Juan Putra, Riccardo A Superina, Max R Langham, Rebecka L Meyers, Greg Tiao, Roshni Dasgupta, Reto Baertschiger
BACKGROUND: Undifferentiated embryonal sarcoma of the liver (UESL) is a rare tumor for which there are few evidence-based guidelines. The aim of this study was to define current management strategies and outcomes for these patients using a multi-institutional dataset curated by the Pediatric Surgical Oncology Research Collaborative. METHODS: Data were collected retrospectively for patients with UESL treated across 17 children's hospitals in North America from 1989 to 2019...
March 31, 2024: Pediatric Blood & Cancer
https://read.qxmd.com/read/38553954/toxicity-due-to-steroid-treatment-in-itp-remains-a-concern
#40
JOURNAL ARTICLE
Henrik Frederiksen
Corticosteroids are the preferred first-line treatment in ITP in guidelines. The analyses by Wang et al. shows that hospital-registered steroid-related toxicity occurs frequently and emphasizes that exposure should be for a limited duration of time. Commentary on: Wang et al. Longitudinal evaluation of adverse events due to steroid use in primary immune thrombocytopenia: a population-based study. Br J Haematol 2024 (Online ahead of print). doi: 10.1111/bjh.19358.
March 30, 2024: British Journal of Haematology
keyword
keyword
169287
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.